Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Platelet thromboxane limits T cell immunity to cancer metastasis via ARHGEF1

ABSTRACT: Platelet thromboxane limits T cell immunity to cancer metastasis via ARHGEF1

PROVIDER: PRJNA1186122 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31349638_1.fastq.gz	Fastqsanger.gz
	SRR31349638_2.fastq.gz	Fastqsanger.gz
	SRR31349639_1.fastq.gz	Fastqsanger.gz
	SRR31349639_2.fastq.gz	Fastqsanger.gz
	SRR31349640_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Platelet thromboxane limits T cell immunity to cancer metastasis via ARHGEF1

Project description:Platelet thromboxane limits T cell immunity to cancer metastasis via ARHGEF1

| PRJNA1186120 | ENA

Platelet thromboxane limits T cell immunity to cancer metastasis via ARHGEF1

Project description:Metastasis is the spread of cancer cells from primary tumours to distant organs and is the cause of 90% of cancer deaths globally. Newly metastasising cancer cells are uniquely vulnerable to immune attack, deprived of the highly immunosuppressive microenvironment of established tumours. There is interest in exploiting this vulnerability to prevent recurrence in early cancer patients at risk of metastasis. Here, we show that inhibition of cyclooxygenase (COX)-1, including with aspirin, enhances immunity to cancer metastasis by releasing T cells from suppression by platelet-derived thromboxane A2 (TXA2). Platelet TXA2 triggers an immunosuppressive pathway within T cells dependent upon the guanine exchange factor ARHGEF1, suppressing T cell receptor (TCR)-driven kinase signalling, proliferation and effector functions. T cell-specific conditional deletion of Arhgef1 in mice increases T cell activation at the metastatic site, provoking immune-mediated rejection of lung and liver metastases. Consequently, restricting the availability of TXA2 using aspirin, selective COX-1 inhibitors or through platelet-specific deletion of COX-1 reduces the rate of metastasis in a manner dependent upon T cell-intrinsic expression of ARHGEF1 and signalling by TXA2 in vivo. These findings reveal a novel immunosuppressive pathway limiting T cell immunity to cancer metastasis, providing a mechanistic basis for the anti-metastatic activity of aspirin and paving the way for more effective anti-metastatic immunotherapies.

2024-12-02 | GSE281885 | GEO

Platelet thromboxane limits T cell immunity to cancer metastasis via ARHGEF1

2024-12-02 | GSE281884 | GEO

NAD+ supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling

Project description:NAD+ supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling

| PRJNA911143 | ENA

Mitochondrial fusion limits breast cancer metastasis

Project description:Mitochondrial fusion limits breast cancer metastasis

| PRJNA1027379 | ENA

Hypoxia stimulates CTC-platelet cluster formation to promote breast cancer metastasis

Project description:Circulating tumor cell clusters/micro-emboli (CTM) possess greater metastatic capacity and survival advantage compared to individual circulating tumor cell (CTCs). However, the formation of CTM subtypes and their role in tumor metastasis remain unclear. In this study, we used a microfluidic Cluster-chip with easy operation and high efficiency to isolate CTM from peripheral blood, which confirmed their correlation with clinicopathological features and identified the critical role of CTC-platelet clusters in BC metastasis. The correlation between platelets and CTM function was further confirmed in a mouse model and RNA-seq of CTM identified high-expressed genes related to hypoxia stimulation and platelet activation which possibly suggested the correlation of hypoxia and CTC-platelet cluster formation. In conclusion, we successfully developed the Cluster-chip platform to realize the clinical capture of CTMs and analyze the biological properties of CTC-platelet clusters, which could benefit the design of potential treatment regimens to prevent CTM-mediated metastasis and tumor malignant progression.

2024-02-28 | GSE256445 | GEO

IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction

Project description:IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction

| PRJNA1037076 | ENA

Lymphatic platelet thrombosis limits bone repair by precluding lymphatic transporting DAMPs

Project description:In the musculoskeletal system, lymphatic vessels (LVs), which are interdigitated with blood vessels, travel and form an extensive transport network. Blood vessels in bone regulate osteogenesis and hematopoiesis, however, whether LVs in bone affect fracture healing is unclear. Here, we investigated the lymphatic draining function at the tibial fracture sites using near-infrared indocyanine green lymphatic imaging (NIR-ICG) and discovered that lymphatic drainage insufficiency (LDI) started on day one and persisted for up to two weeks following the fracture. Sufficient lymphatic drainage facilitates fracture healing. Furthermore, we identified that lymphatic platelet thrombosis (LPT) blocked the draining lymphoid sinus and LVs, caused LDI, and then inhibited fracture healing, which can be rescued by a pharmacological approach. Moreover, unblocked lymphatic drainage decreased neutrophils and increased M2-like macrophages of the hematoma niche to support osteoblast (OB) survival and bone marrow-derived mesenchymal stem cell (BMSC) proliferation via transporting damage-associated molecular patterns (DAMPs). Lymphatic platelet thrombolysis also benefits senile fracture healing. These findings demonstrate that LPT limits bone regeneration by impeding lymphatic transporting DAMPs. Together, these findings represent a novel way forward in the treatment of bone repair.

2024-10-05 | PXD056584 |

Defective flow space limits the scaling up of turbulence bioreactors for platelet generation

Project description:Defective flow space limits the scaling up of turbulence bioreactors for platelet generation

| PRJNA1091907 | ENA

Siah2 control of T-regulatory cells limits anti-tumor immunity

Project description:Siah2 control of T-regulatory cells limits anti-tumor immunity

| PRJNA556492 | ENA